Piperacillin/tazobactam

Drug Profile

Piperacillin/tazobactam

Alternative Names: Tazobac; Tazobactam/piperacillin; Tazobactam/piperacillin 1:8 ratio product; Tazocel; Tazocilline; Tazocin; YP-18; Zosyn

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator NAEJA Pharmaceutical; Taiho Pharmaceutical
  • Developer Taiho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Carboxylic acids; Penicillins; Piperazines
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Biliary tract infections; Cholangitis; Cholecystitis; Febrile neutropenia; Intra-abdominal infections; Nosocomial pneumonia; Peritonitis; Respiratory tract infections; Sepsis; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 31 Dec 2016 Preregistration for Skin and soft tissue infections in Japan (IV) (Taiho Pharmaceutical pipeline, December 2016)
  • 26 Jun 2015 Launched for Febrile neutropenia in Japan (IV)
  • 26 Jun 2015 Registered for Febrile neutropenia in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top